Key result
The anti-CDV-H monoclonal antibody mAb-1347 potently inhibited morbillivirus membrane fusion by blocking the F-triggering function of H-proteins without interfering with receptor binding.
The study reveals the mechanistic requirements for morbillivirus membrane fusion activation and identifies the H-stalk 'spacer' microdomain as a potential antiviral drug target.
May guide morbillivirus antiviral development; leaves open translation beyond animal models.
Despite large vaccination campaigns, measles virus (MeV) and canine distemper virus (CDV) cause major morbidity and mortality in humans and animals, respectively. The MeV and CDV cell entry system relies on two interacting envelope glycoproteins: the attachment protein (H), consisting of stalk and head domains, co-operates with the fusion protein (F) to mediate membrane fusion. However, how receptor-binding by the H-protein leads to F-triggering is not fully understood. Here, we report that an anti-CDV-H monoclonal antibody (mAb-1347), which targets the linear H-stalk segment 126-133, potently inhibits membrane fusion without interfering with H receptor-binding or F-interaction. Rather, mAb-1347 blocked the F-triggering function of H-proteins regardless of the presence or absence of the head domains. Remarkably, mAb-1347 binding to headless CDV H, as well as standard and engineered bioactive stalk-elongated CDV H-constructs treated with cells expressing the SLAM receptor, was enhanced. Despite proper cell surface expression, fusion promotion by most H-stalk mutants harboring alanine substitutions in the 126-138 "spacer" section was substantially impaired, consistent with deficient receptor-induced mAb-1347 binding enhancement. However, a previously reported F-triggering defective H-I98A variant still exhibited the receptor-induced "head-stalk" rearrangement. Collectively, our data spotlight a distinct mechanism for morbillivirus membrane fusion activation: prior to receptor contact, at least one of the morbillivirus H-head domains interacts with the membrane-distal "spacer" domain in the H-stalk, leaving the F-binding site located further membrane-proximal in the stalk fully accessible. This "head-to-spacer" interaction conformationally stabilizes H in an auto-repressed state, which enables intracellular H-stalk/F engagement while preventing the inherent H-stalk's bioactivity that may prematurely activate F. Receptor-contact disrupts the "head-to-spacer" interaction, which subsequently "unlocks" the stalk, allowing it to rearrange and trigger F. Overall, our study reveals essential mechanistic requirements governing the activation of the morbillivirus membrane fusion cascade and spotlights the H-stalk "spacer" microdomain as a possible drug target for antiviral therapy.
No takes yet. Share an insight, caveat, or question.
Ader-Ebert et al. (2015) studied Morbillivirus infection. mAb-1347 vs. Control mAbs or no antibody was evaluated on Membrane fusion (virus-to-cell and cell-to-cell). The anti-CDV-H monoclonal antibody mAb-1347 potently inhibited morbillivirus membrane fusion by blocking the F-triggering function of H-proteins without interfering with receptor binding.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: